Plain-English translation of NCT06834126 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 trial testing combined with radiation therapy for advanced rectal cancer. is an experimental medication designed to improve how radiation works by reducing low-oxygen areas in tumors that can resist treatment. The goal is to find the right dose of this medication and learn whether it helps patients avoid surgery while achieving better cancer control.
Some rectal cancers develop areas with very low oxygen levels, which can make them harder to treat with radiation alone. This trial is exploring whether this medication can reduce those low-oxygen areas and make radiation therapy more effective, potentially allowing more patients to keep their rectum rather than needing surgery.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either standard radiation therapy alone, or radiation therapy combined with infusions. The medication arm involves IV infusions before and during your radiation week, with radiation given five days a week for one week. After radiation, you'll receive standard chemotherapy for 3–4 months. Throughout the trial, you'll have imaging scans, blood draws, tissue biopsies, stool samples collected, and a special MRI scan to measure oxygen levels in your tumor. If your cancer doesn't fully respond, you may undergo surgery as early as four weeks after completing chemotherapy.
AI-generated summary from trial data · Aug 12, 2026 · Not medical advice
United States